Bionews Staff,  writers and editors—

Bionews, the owner and publisher of this site, employs science writers and editors, most of whom have PhDs in the life sciences, as well as veteran journalists, who ensure stories are well-written and easy to understand. Our stories undergo a comprehensive fact-checking and editing process to confirm accuracy, objectiveness, and thoroughness in order to best serve our audience of patients and caregivers.

Articles by Bionews Staff

#ACTRIMS2019 – Jeffrey Cohen, MD, is New President of ACTRIMS

Jeffrey Cohen, MD, director of the experimental therapeutics program at the Mellen Center for Multiple Sclerosis Treatment and Research at the Cleveland Clinic, is the newly named  president of ACTRIMS, the Americas Committee for Treatment and Research in Multiple Sclerosis. Cohen’s appointment concluded the 2019 ACTRIMS Forum that ran…

FDA Grants ‘Breakthrough Therapy’ Designation to Genentech’s Ocrelizumab for PPMS

Genentech recently announced that the U.S. Food and Drug Administration (FDA) granted its investigational medicine ocrelizumab, a potential treatment for primary progressive multiple sclerosis (PPMS), Breakthrough Therapy Designation based on positive Phase 3 clinical trial results showing that ocrelizumab significantly reduced disability progression and other disease activity markers compared to placebo. The FDA designation is…

Mike Nace, Editor-in-Chief of Multiple Sclerosis News Today, Reviews Day 2-3 at #ECTRIMS2015

https://multiplesclerosisnewstoday.com/wp-content/uploads/2015/10/ECTRIMS-Podcast-2-091015-8.32-pm.mp3   Read the articles mentioned in the podcast: #ECTRIMS2015 – Another Attendee Record #ECTRIMS2015 – “Vitamin D plays important role in MS inflammation.” – Jorge Correale #ECTRIMS2015 – “When you stop smoking you can decrease the risk of disease progression.” – Jorge Correale Discovering a New World in…

Spasticity Drug to be Tested on Multiple Sclerosis Patients in Early 2015

Concert Pharmaceuticals, Inc. will announce their latest results from the Phase 1 data of CTP-354, a drug developed to treat spasticity — a chronic condition associated with patients with brain disorders, including Multiple Sclerosis — at the next American Neurological Association’s Annual Meeting in Baltimore, Maryland. The Phase 1 randomized,…

New Multiple Sclerosis Drug Target of U.S. and Japanese Researchers

The National Center of Neurology and Psychiatry, based in Japan, announced that they will initiate a 3-month clinical trial on 9 patients with multiple sclerosis, beginning in March. Multiple sclerosis is an autoimmune disease caused by mutations of lymphocyte immune cells, which attack and destroy a patient’s own nerve cells. Patients with multiple sclerosis typically…

Benefits of Cognitive Reserve in Multiple Sclerosis May Also Benefit TBI Patients

Researchers from the Kessler Foundation have found that higher educational achievement reduces the negative impact of traumatic brain injury (TBI) on cognitive status. The study appeared in Archives of Physical Medicine & Rehabilitation. It was reported in the study that cognitive ability after experiencing TBI differs in individuals even when their injury levels were comparable. As…